Results 61 to 70 of about 483,075 (302)

Raised serum transaminases during treatment with pegylated interferon for chronic hepatiti C [PDF]

open access: yes, 2016
Introduction : Serum transaminases rose significantly in 7 patients with chronic hepatitis C, genotypes 2 and 3, who were treated with pegylated interferon and ribavirin. Methods : 219 patients with chronic hepatitis C, genotypes 2 and 3, were treated
Datta, S.   +3 more
core   +1 more source

TRMT6‐Mediated m1A Modification of CDK9 mRNA Is a Dual‐Pronged Pathogenic Driver for HBV‐Related Hepatocellular Carcinoma

open access: yesAdvanced Science, EarlyView.
TRMT6‐mediated m1A modification in CDK9 mRNA enhances its mRNA stability and translation efficiency, thereby increasing the protein levels of CDK9. Upregulated CDK9 promotes the progression of HCC by elevating the levels of oncogenic factors including p‐STAT3, MCL1, and BCL‐2. On the other hand, CDK9 phosphorylates TARDBP at Ser254 to activate HBV core
Rui Zhang   +12 more
wiley   +1 more source

Transcription Factor MafB Suppresses Type I Interferon Production by CD14+ Monocytes in Patients With Chronic Hepatitis C

open access: yesFrontiers in Microbiology, 2019
Transcription factor MafB regulates differentiation and activity of monocytes/macrophage and is associated with the development of atherosclerosis and cancers.
Tie-Mei Liu   +3 more
doaj   +1 more source

Clinical epidemiology of extrahepatic manifestations of chronic hepatitis C virus infection

open access: yesМедицинский совет, 2020
Extrahepatic manifestations occur in more than half of patients with chronic hepatitis C virus infection and may be no less dangerous to the health and life of the patient than the isolated pathology of the liver.
V. V. Tsvetkov   +2 more
doaj   +1 more source

Vitamin D as One of Predicators of the Stable Viral Response to Antiviral Therapy in Patients with Chronis Hepatitis С [PDF]

open access: yes, 2016
Chronic hepatitis C (CHC) it is not exceptionally medical problem but a significant social and economic threat, taking into account the unfavorable consequences of this disease: cirrhosis and hepatocellular carcinoma.
Androsova, O. (Olga)   +3 more
core  

Antimitochondrial antibody -M2 positive autoimmune hepatitis during standard of care for chronic hepatitis C. [PDF]

open access: yes, 2012
The current standard of care (SoC) for chronic hepatitis C, i.e. the combination of a pegylated-interferon (PEG-IFN) with ribavirin (RBV), may activate underlying autoimmune conditions.
ALESSI, Nicola   +2 more
core   +1 more source

Multicohort Validation of Gut Microbiome Signatures for Cholangiocarcinoma Diagnosis and Functional Characterization of Bifidobacterium Pseudocatenulatum

open access: yesAdvanced Science, EarlyView.
This study analyzes gut bacteria in cholangiocarcinoma patients, revealing distinct microbial signatures that enable accurate disease detection. Species‐based diagnostic models achieved over 98% accuracy in identifying cholangiocarcinoma and distinguished it from other liver diseases. The research demonstrates that specific beneficial bacteria suppress
Benchen Rao   +18 more
wiley   +1 more source

Health-Related Quality of Life in Portuguese Patients with Chronic Hepatitis C [PDF]

open access: yes, 2016
INTRODUCTION: Chronic hepatitis C virus (HCV) infection impacts multiple health and psychosocial dimensions and encompasses a significant overall burden as it progresses to advanced stages of hepatic disease.
Pedroto, I., Rei, A., Rocha, M.
core   +1 more source

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

open access: yesAdvanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey   +6 more
wiley   +1 more source

Thrombocytopenia in end-stage renal disease and chronic viral hepatitis B or C [PDF]

open access: yes, 2018
Objectives. We evaluated platelet counts in end-stage renal disease and chronic viral hepatitis. Materials and Methods. We studied 70 patients with end-stage renal disease and chronic viral hepatitis and compared them to a control group of 45 patients ...
Breaban, Iulia   +12 more
core   +1 more source

Home - About - Disclaimer - Privacy